FDA’s Next Accelerated Approval Process: “Targeted Cancer Drugs”?
SAN ANTONIO - Former FDA Commissioners David Kessler and Mark McClellan are urging the agency to develop a new process for accelerated cancer drug approval to take advantage of biomarker identification of specific patient populations and drug activity
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
Multiple simultaneous sponsors, foreshortened regulatory reviews, and a packet of unanswered post-approval efficacy issues make for what should be very competitive – and inherently comparative – post-market assessment period for the upcoming SARS-CoV-2 vaccines.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.